Clinical and genotypic findings in HIV-infected patients with the k65r mutation failing first-line antiretroviral therapy in Nigeria

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 2, 2009, Pages 228-234

  Hawkins, Claudia A ^a   Chaplin, Beth ^b   Idoko, John ^c   Ekong, Ernest ^d   Adewole, Isaac ^e   Gashau, Wadzani ^f   Murphy, Robert L ^a   Kanki, Phyllis ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF JOS   (Nigeria)

^d NIGERIAN INSTITUTE OF MEDICAL RESEARCH   (Nigeria)

^e UNIVERSITY OF IBADAN   (Nigeria)

^f UNIVERSITY OF MAIDUGURI   (Nigeria)

Author keywords

Drug mutations; K65R; Non B HIV 1 subtypes

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ASSESSMENT; DRUG TREATMENT FAILURE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MUTATION; NIGERIA; PRIORITY JOURNAL;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NIGERIA; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; YOUNG ADULT;

EID: 70349656911     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b06125     Document Type: Article

References (31)

1. Johnson VA, Brun-Vezinet F, Clotet B, et al, and the International AIDS Society-USA Drug Resistance Mutations Group. Update of the drug resistance mutations in HIV-1. Top HIV Med. 2008;16:138-145. Review.
2. Gupta R, Chrystie I, O'Shea S, et al. K65R and Y181C are less prevelant in HAART-experienced HIV-1 subtype A patients. AIDS. 2005; 19:1916-1918.
3. Gallant JE, Dejesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl Med. 2006;354:251-260.
4. Eron JJ. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. J Infect Dis. 2008;197(Suppl 3):S261-S271.
5. Gallant JE, Deresinski S. Tenofovir disproxil fumarate. Clin Infect Dis. 2003;37:944-995.
6. Winston A, Pozniak A, Mandalia S, et al. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV- reverse transcriptase. AIDS. 2004;18:949-951.
7. Valer L, Martin-Carbonero L, de Mendoza C, et al. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. AIDS. 2004;18:2094-2096.
8. Gianotti N, Seminari E, Fusetti G, et al. Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients. AIDS. 2004;18:2205-2208.
9. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335-1342.
10. Brenner B, Oliveria M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006; 20:F9-F13.
11. Miller MD, Margot N, McColl D, et al. K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials. AIDS. 2007;21:265-266.
12. Sungkanuparph S, Manosuthi W, Kiertibuanakul S, et al. Prevalance and risk factors for developing K65R'mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination stavudine, lamivudine and nevirapine. J Clin Virol. 2008;41:310-313.
13. de Mendoza C, Garrido C, Corral A, et al. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses. 2007;23:879-885.
14. Geretti AM. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis. 2007;20:22-32. Review.
15. Maslin J, Rogier C, Caron M, et al. Antiretroviral drug resistance among drug-naive HIV-1-infected individuals in Djibouti (Horn of Africa). Antivir Ther. 2005;10:855-859.
16. Garcia-Lerma JG, MacInnes H, Bennett D, et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol. 2003;77:5685-5693.
17. Margot NA, Lu B, Cheng A, et al, and the Study 903 Team. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med. 2006;7:442-450.
18. Pillay V, Pillay C, Kantor R, et al. HIV-1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1449-1454.
19. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother. 2006;50:4182-4185.
20. Roge BT, Katzenstein TL, Obel N, et al. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther. 2003;8:173-182.
21. Trotta MP, Bonfigli S, Ceccherini-Silberstein F, et al. Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir. Journal of Medical Virology. 2006;78: 535-541.
22. Zolopa AS, RheeY, Shin D, et al. The association of the K65R with Q151M and the relationship to antiretroviral treatment: results from northern California clinic population. [Abstract 83]. Antivir Ther. 2004;9:S94.
23. Boucher S, Recordon-Pinson P, Ragnaud JM, et al. HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation. HIV Med. 2006;7:294-298.
24. Zaccarelli M, Federico Perno C, Forbici F, et al. Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy. Clin Infect Dis. 2004;38:433-437.
25. Villena C, Prado JG, Puertas MC, et al. Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region. J Virol. 2007;81:4713-4721.
26. Masquelier B, Race E, Tamalet C, et al. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. Antimicrob Agents Chemother. 2001;45:1836-1842. (Pubitemid 32466357)
27. Imamichi T, Sinha T, Imamichi H, et al. High level resistance to 3'-azido- 3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. J Virol. 2000;74:1023-1028.
28. Parikh UM, Bacheler L, Koontz D, et al. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol. 2006; 80:4971-4977.
29. Parikh UM, Barnas DC, Faruki H, et al. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis. 2006;194:651-660.
30. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005;40:280-287.
31. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006; 20:F9-F13.